EGFR and colorectal carcinoma: In a recent study, Qiong Li et al. investigated the mechanism underlying the disappointing effect of the EGFR inhibitor gefitinib in CRC cells, and found that STAT3 phosphorylation (pSTAT3) highly correlated with gefitinib resistance in CRC cells [72].